Local and systemic effects of inhaled AZD9164 compared with tiotropium in patients with COPD

Respiratory Medicine

Volumn 107, Issue 1, 2013, Pages 84-90

  Bjermer, Leif ^a   Bengtsson, Thomas ^b   Jorup, Carin ^b   Lötvall, Jan ^c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

AZD9164; Bronchodilator; COPD; FEV1; Muscarinic antagonist; Tiotropium

Indexed keywords

AZD 9164; IPRATROPIUM BROMIDE; MUSCARINIC RECEPTOR BLOCKING AGENT; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINGLE DRUG DOSE; THORAX PAIN; THROAT IRRITATION; THROMBOPHLEBITIS; TREMOR;

ADMINISTRATION, INHALATION; AGED; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PIPERIDINES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINUCLIDINES; RECEPTOR, MUSCARINIC M3; SCOPOLAMINE DERIVATIVES;

EID: 84871371932     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2012.09.014     Document Type: Article

References (11)

1. R. Rodriguez-Roisin Global strategy for the diagnosis, management and prevention of COPD global initiative for chronic obstructive lung disease (GOLD) 2011 GOLD Committee
2. P. Barnes The pharmacological properties of tiotropium Chest 117 Suppl. 2000 63S 66S
3. R. Gosens, J. Zaagsma, H. Meurs, and A.J. Halayko Muscarinic receptor signaling in the pathophysiology of asthma and COPD Respir Res 7 2006 73
4. K.E. Belmonte Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease Proc Am Thorac Soc 2 2005 297 304
5. A. Anzueto, D. Tashkin, S. Menjoge, and S. Kesten One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium Pulm Pharmacol Ther 18 2 2005 75 81
6. R. Gosens, I.S. Bos, J. Zaagsma, and H. Meurs Protective effects of tiotropium bromide in the progression of airway smooth muscle remodeling Am J Respir Crit Care Med 171 10 2005 1096 1102
7. D.P. Tashkin, B. Celli, S. Senn, D. Burkhart, S. Kesten, and S. Menjoge A 4-year trial of tiotropium in chronic obstructive pulmonary disease New Engl J Med 359 15 2008 1543 1554
8. B.C. Moulton, and A.D. Fryer Muscarinic receptor antagonists, from folklore to pharmacology; finding drugs that actually work in asthma and COPD Br J Pharmacol 163 2011 44 52
9. S. Singh, Y.K. Loke, P.L. Enright, and C.D. Furberg Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials Available from: BMJ Online First [serial on the Internet] 342 d3215 2011 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3114950/pdf/bmj.d3215.pdf
10. A. Mete, K. Bowers, E. Chevalier, D.K. Donald, H. Edwards, and K. Escott The discovery of AZD9164, a novel muscarinic M3 antagonist Bioorg Med Chem Lett 21 24 2011 7440 7446
11. Data on file 2012 AstraZeneca